drugset
drugset / Trial / NCT01444716

Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia

NCT01444716 ↗

Phase 2 Completed 34 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well ofatumumab works as front-line therapy in treating elderly participants with chronic lymphocytic leukemia. Monoclonal antibodies, such as ofatumumab, may interfere with the ability of cancer cells to grow and spread.

Timeline

Start
2011-12-15
Primary completion
2020-06-11
Completion
2020-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ofatumumab Monoclonal antibody — Intravenous

Indications

B-cell chronic lymphocytic leukemia